-
Posted by
Two Blokes Jun 30 -
Filed in
Stock
-
7 views
Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With Abbott acquiring rights to 4 more biosimilar products and a double-digit CAGR in the target biosimilar emerging markets, the EPD business could stimulate EPS growth beyond Medical Devices. With an excellent balance sheet and over 50 consecutive years of dividend increases, Abbott is a robust long-term investment for income investors.
